It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Necroptosis facilitates cell death in a controlled manner and is employed by many cell types following injury. It plays a significant role in various liver diseases, albeit the cell-type-specific regulation of necroptosis in the liver and especially hepatocytes, has not yet been conceptualized. We demonstrate that DNA methylation suppresses RIPK3 expression in human hepatocytes and HepG2 cells. In diseases leading to cholestasis, the RIPK3 expression is induced in mice and humans in a cell-type-specific manner. Overexpression of RIPK3 in HepG2 cells leads to RIPK3 activation by phosphorylation and cell death, further modulated by different bile acids. Additionally, bile acids and RIPK3 activation further facilitate JNK phosphorylation, IL-8 expression, and its release. This suggests that hepatocytes suppress RIPK3 expression to protect themselves from necroptosis and cytokine release induced by bile acid and RIPK3. In chronic liver diseases associated with cholestasis, induction of RIPK3 expression may be an early event signaling danger and repair through releasing IL-8.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Jena University Hospital, Department of Anesthesiology and Intensive Care Medicine, Nanophysiology Group, Jena, Germany (GRID:grid.275559.9) (ISNI:0000 0000 8517 6224); Jena University Hospital, Center for Sepsis Control and Care, Jena, Germany (GRID:grid.275559.9) (ISNI:0000 0000 8517 6224)
2 Jena University Hospital, Center for Sepsis Control and Care, Jena, Germany (GRID:grid.275559.9) (ISNI:0000 0000 8517 6224); Jena University Hospital, Department of Clinical Chemistry and Laboratory Diagnostics, Jena, Germany (GRID:grid.275559.9) (ISNI:0000 0000 8517 6224)
3 Jena University Hospital, Pathology, Jena, Germany (GRID:grid.275559.9) (ISNI:0000 0000 8517 6224)
4 Jena University Hospital, Department of Anesthesiology and Intensive Care Medicine, Nanophysiology Group, Jena, Germany (GRID:grid.275559.9) (ISNI:0000 0000 8517 6224); Jena University Hospital, Center for Sepsis Control and Care, Jena, Germany (GRID:grid.275559.9) (ISNI:0000 0000 8517 6224); Friedrich Schiller University Jena, Faculty of Medicine, Jena, Germany (GRID:grid.9613.d) (ISNI:0000 0001 1939 2794)